Edgewise Therapeutics, Inc.
EWTXDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
How EWTX's past catalysts played out
EDG-7500
Hypertrophic Cardiomyopathy
Sevasemten 10 mg
Becker Muscular Dystrophy
Sevasemten Dose 1
Duchenne Muscular Dystrophy
Sevasemten Dose 2
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EDG-7500 | Phase 2 | Hypertrophic Cardiomyopathy | - | - |
Sevasemten 10 mg | Phase 2 | Becker Muscular Dystrophy | - | - |
Sevasemten Dose 1 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Sevasemten Dose 2 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Edgewise Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Edgewise Therapeutics, Inc.'s (EWTX) pipeline across Phase 2. Its lead program is EDG-7500 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Edgewise Therapeutics, Inc.'s next FDA catalyst?→
Edgewise Therapeutics, Inc.'s (EWTX) next tracked catalyst is a Phase 2 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EWTX biotech catalysts?→
Add EWTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Edgewise Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.